Recombinant Human KLRC3 Protein，His

KLRC3, also known as NKG2C, is a member of the natural killer (NK) cell receptor family, primarily involved in the immune response against cancerous and infected cells. Research into KLRC3 recombinant proteins has gained considerable attention due to their potential therapeutic applications in immunotherapy. The functional diversity of KLRC3, particularly its ability to regulate NK cell activation and cytotoxicity, makes it a crucial target for enhancing anti-tumor immunity. Studies have shown that KLRC3 interacts with a range of ligands, both in healthy and pathological conditions, influencing immune cell signaling pathways. Moreover, variations in KLRC3 expression levels have been associated with different cancer types and outcomes, prompting investigations into its role as a biomarker for cancer prognosis and as a target for novel therapeutic strategies. Recombinant KLRC3 proteins can be engineered to assess their functional properties, improve understanding of their interaction with ligands, and ultimately aid in the development of NK cell-based therapies. As researchers explore the intricacies of KLRC3’s mechanisms in immune modulation, the insights gained could lead to enhanced cancer treatments and improved patient outcomes. The growing interest in KLRC3 underscores its significance in immunology and its promising potential in clinical applications.